118 results about "Continuous infusion" patented technology

When using a drug container having an identification tag fixed or detachably provided at a predetermined position of the container, the tag having drug data on a kind and a concentration of a drug and both or one of upper and lower limits of a flow rate on a continuous infusion and the upper and lower limits, time and flow rate on a one-shot administration recorded thereon, it is possible to ensure safety by prompting for a stop of injection by a warning when a setting beyond the upper and lower limits is performed and rewrite a liquid infusing time and a flow rate and so on required to be set according to symptoms of a patient.

The present invention generally relates to radio-enabled devices for detection and remedy of biological and chemical warfare attack. More particularly, this invention relates to an on-body apparatus that provides a means of treatment which is innocuous to the wearer, but capable of injecting antidotes within seconds and preferably also combines multiple means of sensing chemical and biological agents as well as monitoring user's physiological response to the antidotes thereby to enable tailored and continuous infusion of antidotes while minimizing the side effect of the antidotes themselves. A key embodiment of this invention is the incorporation of an electronically-controlled needle or cannula that will deploy only when commanded to. When not deployed, the device sits inertly against the patient's skin, affixed by adhesive and or elastic materials.

The present invention relates to the development of a pharmacological non-human animal model that associates memory loss to histopathological features found in the brain of a subject having Alzheimer's Disease. In one embodiment, a four-week continuous infusion of a Fe2+, Aβ42 and buthionine sulfoximine (FAB) solution in the left ventricle of young adult Long-Evans rats induced memory impairment accompanied by increased hyperphosphorylated Tau protein levels in cerebrospinal fluid. Brains from treated animals displayed neuritic plaques, tangles, neuronal loss, astrogliosis and microgliosis in hippocampus and cortex. The present invention may be utilized in evaluating preventive, therapeutic and diagnostic means for neurologic diseases.

The invention relates to a continuous liquid infusion device which can be easily prepared for operation with small force, and can infuse liquid at constant infusion rate and amount over a long time. It comprises a liquid syringe section and a driving pump section mounted on the liquid syringe section, wherein sliding the pressing arm of the driving pump section upward leads to axially slides the piston in the negative pressure chamber to produce a negative pressure therein; and using returning force of the piston under the negative pressure, the liquid pushout plunger barrel is biased toward the upper edge of a pressing member through a locking member engaged with the piston so as to push out liquid in the liquid syringe from the liquid infusion port. Further, only the liquid syringe is disposable while the vacuum pump barrel on the driving side is good for repeated use (reusable).

The invention relates to a continuous liquid infusion device which can be easily prepared for operation with small force, and can infuse liquid at constant infusion rate and amount over a long time. It comprises a liquid syringe section and a driving pump section mounted on the liquid syringe section, wherein sliding the pressing arm of the driving pump section upward leads to axially slides the piston in the negative pressure chamber to produce a negative pressure therein; and using returning force of the piston under the negative pressure, the liquid pushout plunger barrel is biased toward the upper edge of a pressing member through a locking member engaged with the piston so as to push out liquid in the liquid syringe from the liquid infusion port. Further, only the liquid syringe is disposable while the vacuum pump barrel on the driving side is good for repeated use (reusable).

A method for automatically adjusting PCA (patient controlled analgesia) infusion parameters of an electronic infusion pump comprises following steps: step S1, the number of generation times of PCA activation signals is acquired through a PCA assembly in a preset timing cycle; step S2, whether the times of the PCA activation signals in the preset timing cycle are smaller than or equal to a lower threshold of the times, are larger than the lower threshold of the times and smaller than an upper threshold of the times, or are larger than or equal to the upper threshold of the times is judged, a step S3 is executed when the times are smaller than or equal to the lower threshold of the times, a step S4 is executed when the times are larger than the lower threshold of the times and smaller than the upper threshold of the times, and a step S5 is executed when the times are larger than or equal to the upper threshold of the times; step S4, the continuous infusion amount keeps a current value; step S5, the current continuous infusion amount is progressively increased once according to a preset second dosage. According to the method, the continuous infusion amount can be adjusted according to PCA activation operation of a patient, so that the defect of excessive analgesia or insufficient analgesia is overcome, and the method is safer and more convenient.

A micropump according to the invention uses an eccentric cam member rotating within a pump housing to sequentially open and close valves in the pump housing to withdraw fluid from a reservoir and provide metered amounts of the fluid to a cannula port for administration to a patient. The micropump may be used in a disposable pump for continuous infusion of medication such as insulin.

Compositions containing a carrier and microbubbles encapsulating one or more gases, preferably oxygen, and methods for making and using the compositions are described herein. The microbubbles contain a lipid envelope. The compositions may be administered to a patient to quickly deliver large amounts of oxygen to the patient's blood supply or directly to a tissue in need of oxygen. The compositions may be administered via injection or as a continuous infusion. The compositions contain a concentrated microbubble suspension, where the suspension contains at least 40 mL oxygen / dL suspension. The microbubbles are preferably less than 20 microns in diameter, more preferably less than 15 microns in diameter. The microbubbles described herein may be administered to a patient in an effective amount to increase in oxygen concentration in the patient's blood, and / or one or more tissues or organs.

The present invention relates to preparations and methods for treating a GD2 positive cancer by administering a preparation comprising a chimeric or humanized anti-GD2 antibody to a patient, wherein the patient is not concomitantly treated with interleukin-2 (IL-2 wherein a GD2 positive cancer is treated in the patient. Furthermore, the invention relates to preparations and methods for the treatment of a GD2 positive cancer in a patient, wherein a preparation comprising an anti-GD2 antibody is administered to the patient as a continuous infusion, without concomitantly administering IL-2. The present invention further relates to preparations and methods for the treatment of a GD2 positive cancer in a patient, wherein the one or more anti-GD2 antibody treatment periods is / are preceded, accompanied, and / or followed by one or more treatment periods with a retinoid.

The invention provides regimens and methods for the treatment of cancer comprising continuous infusion of coenzyme Q10. The coenzyme Q10 may be administered as a monotherapy, or in combination with an additional agent, such as an anticancer agent, a chemotherapeutic agent, or an anti-angiogenic agent. The coenzyme Q10 may be administered at two or more different rates.

The invention relates to a two-channel transfusion head of automatically controlling liquid and gas to be transfused by time phases. The two-channel transfusion head comprises an independently used transfusion head body or at least two transfusion head bodies serially connected for use. A pure gas channel and a pure liquid channel are arranged in each transfusion head body, wherein the top end of each pure gas channel is open; the bottom end of each pure gas channel is provided with a floating valve chest communicated with the bottom end of the pure gas channel; a floating valve which vertically floats is arranged in the floating valve chest; one side of each floating valve chest is communicated with a gas / liquid inlet; the top end of each pure liquid channel is also open; the bottom end of each pure liquid channel is communicated with a gas / liquid outlet; and the bottom part of each pure liquid channel is also communicated with the bottom end of the corresponding floating valve chest. According to the two-channel transfusion head of automatically controlling the liquid and the gas to be transfused by time phases, the goal that the liquid and the gas pass through the transfusion head by time phases and by channels is realized; automatic control is realized during the whole process; the goal that multiple bottles of liquid can be connected in series to be continuously transfused is achieved, and therefore, the problem that liquids are mixed when the multiple bottles of liquid are connected in series to be continuously transfused is avoided, bottle replacing operations of nurses can be reduced, and the labor strength of the nurses can be relieved.

The invention provides regimens and methods for the treatment of cancer comprising continuous infusion of coenzyme Q10. The coenzyme Q10 may be administered as a monotherapy, or in combination with an additional agent, such as an anticancer agent, a chemotherapeutic agent, or an anti-angiogenic agent. The coenzyme Q10 may be administered at two or more different rates.